The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization in U.S. infants. The U.S. Food ...

The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year ...

The protein language model is trained solely on paired human antibody sequences with scalable applications in antibody ...

The simplicity of Merck's monoclonal antibody for RSV in infants could be a plus in its competition with AstraZeneca's ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

Recent innovations across the multiple ADC components, such as enhanced antibody-targeting to the tumors, better linker ...

Results from a first-in-human Phase Ia/Ib trial show that LY4170156 demonstrated a notably high overall response rate in ...

Study reveals the advantages and pitfalls of adding a TKI to a monoclonal antibody after chemoradiation for non-small cell ...

The results feed into an effort to identify to monoclonal antibody combinations that would prevent and possibly treat HIV ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.